Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies.
about
Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancerALK inhibitors in non-small cell lung cancer: the latest evidence and developmentsBiomarkers in phase I-II chemoprevention trials: lessons from the NCI experiencePatterns of Chromosomal Aberrations in Solid TumorsBeyond ALK-RET, ROS1 and other oncogene fusions in lung cancerTumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectivesCurrent and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptorsGenomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFRLung cancer: prevalent trends & emerging conceptsSerum anti-MDM2 and anti-c-Myc autoantibodies as biomarkers in the early detection of lung cancer.PIAS3 expression in squamous cell lung cancer is low and predicts overall survival.Cancer cell-specific oligopeptides selected by an integrated microfluidic system from a phage display library for ovarian cancer diagnosis.Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy.Routine genetic testing of lung cancer specimens derived from surgery, bronchoscopy and fluid aspiration by next generation sequencing.Improving molecular testing and personalized medicine in non-small-cell lung cancer in OntarioHigh BMI1 mRNA expression in peripheral whole blood is associated with favorable prognosis in advanced non-small cell lung cancer patientsMultiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study.Molecular Testing of Lung CancersInterferon induced transmembrane protein 3 regulates the growth and invasion of human lung adenocarcinoma.Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung CancerScreening of ROS1 rearrangements in lung adenocarcinoma by immunohistochemistry and comparison with ALK rearrangements.Oncogenic mutations are associated with histological subtypes but do not have an independent prognostic value in lung adenocarcinomaBiomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers.Current concepts on the molecular pathology of non-small cell lung carcinoma.Great challenges in molecular medicine: toward personalized medicine.Guidance for laboratories performing molecular pathology for cancer patients.Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR statusRecent advances in personalized lung cancer medicine2-diethylaminoethyl-dextran methyl methacrylate copolymer nonviral vector: still a long way toward the safety of aerosol gene therapy.The evolving genomic classification of lung cancer.Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms.Medical care costs incurred by patients with smoking-related non-small cell lung cancer treated at the National Cancer Institute of Mexico.Development of a semi-conductor sequencing-based panel for genotyping of colon and lung cancer by the Onconetwork consortiumDifferent effects of LDH-A inhibition by oxamate in non-small cell lung cancer cellsCirculating Ang-2 mRNA expression levels: looking ahead to a new prognostic factor for NSCLC [corrected]Challenges of coverage policy development for next-generation tumor sequencing panels: experts and payers weigh in.Molecular methods for somatic mutation testing in lung adenocarcinoma: EGFR and beyondGefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.Potential crosstalk between cofilin-1 and EGFR pathways in cisplatin resistance of non-small-cell lung cancerThe efficacy of combining antiangiogenic agents with chemotherapy for patients with advanced non-small cell lung cancer who failed first-line chemotherapy: a systematic review and meta-analysis
P2860
Q26746010-A6C013A3-2F47-47F5-8B86-35A5679C84DEQ26769879-34FA1F01-CF72-40ED-9DE1-2489123C88E1Q26774585-9CD60FDB-F15E-4080-9FCB-76D2C30A1A18Q26786127-714258B3-9AE6-4BC1-A974-FEC052284201Q26851421-2150C488-0FDC-4756-83F3-EFFBAD64C6ADQ27014117-85C1C2D4-4497-43A4-A3E2-79DB39D2FE2FQ28086768-92161ED3-F9E4-4AB8-B74B-6F0DB667941AQ28086993-83BAA3D8-5DF8-45DD-B1F5-20C7993A7606Q28392286-35A3D88A-F43B-40C2-B66E-EDBC32409D29Q30353143-8E39D6EE-4021-4D23-B6BD-4FD2BE51F5B1Q30405870-E723592C-0863-43D5-9773-BB53CC9E2936Q30418500-34679C06-B8AD-4183-91CB-33D3B0AD372EQ33438820-3CEE4DFA-1890-4F41-99B7-764D8CECA3AAQ33599057-7AE4B9A0-4F91-410B-929E-8EED62B97FE8Q33611088-B53C8EC1-E89A-4A3C-9DCB-1549100D3858Q33648891-DD274311-DF4A-49D2-84F5-5488167037BDQ33688612-6E80EA4C-9216-408D-810B-4D482D63D3FAQ33729715-2470650C-761E-4B73-875B-4B809182E249Q33863411-071AB921-90F5-46BC-955D-53B031C215C2Q33873095-38B47058-1058-422C-ACFE-333FFD122637Q33945982-D3BE16D5-084F-4B86-B46A-F3D3F69F9BD4Q34073766-E7823E6E-20AC-42FE-B4B3-1D7A9C6D02A7Q34248282-DC9E3B76-51A0-469C-803F-01F8A27F59B3Q34310062-9EBE9888-0C55-4D54-913C-CB08372B001FQ34391221-9896558E-9B8B-4870-BFCB-C3705B73D3A6Q34431280-4A7EDE41-FB7E-4228-89C9-92552753AA24Q34473831-6C52E718-4AED-487B-A6E0-3D854801B5F4Q34678073-1B8E5C12-F649-4BB2-809E-687E279693C8Q34747045-FA21E421-22CF-4F3D-B2E1-7079DBF9C685Q34852043-8320B01E-86DE-4A82-A544-CC4AF353DE47Q34871953-19E619BA-7E66-4F96-AB31-694876D212FDQ35048098-89174546-E7A0-4417-9672-434B63BFCCA2Q35053271-AB1A744A-E3EA-4780-B29D-EDF0A8F3DD0EQ35068068-367ECCC9-0F95-49C1-9061-AB2C4EB11D62Q35108561-76D01067-0067-4D36-A1DC-3FC9A73BEA12Q35213023-27BAA989-63CE-4DF6-B970-3E7235DF9C7CQ35256622-3CDB2C5D-D620-4F0F-8B07-955237752EA3Q35345489-9A73E26E-9433-429C-991A-4316143B07B7Q35551805-85EFB9D0-F6D7-4056-B7AF-EC4311B3190FQ35649624-9AFA768F-1633-40D2-A7CA-52BCA6C1F083
P2860
Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Genotyping and genomic profili ...... current and future therapies.
@ast
Genotyping and genomic profili ...... current and future therapies.
@en
type
label
Genotyping and genomic profili ...... current and future therapies.
@ast
Genotyping and genomic profili ...... current and future therapies.
@en
prefLabel
Genotyping and genomic profili ...... current and future therapies.
@ast
Genotyping and genomic profili ...... current and future therapies.
@en
P2093
P2860
P356
P1476
Genotyping and genomic profili ...... current and future therapies.
@en
P2093
Hsing-Jien Kung
Philip C Mack
Tianhong Li
P2860
P304
P356
10.1200/JCO.2012.45.3753
P407
P577
2013-02-11T00:00:00Z